Table 1 Patient characteristics
Clinical data (n=58) | |
Age (years) | 69.50 ± 7.80 |
Male (n, %) | 47 (81.0) |
Body mass index (kg/m2) | 29.70 ± 3.57 |
Body surface area (m2) | 2.04 ± 0.18 |
Waist circumference (cm) | 104.31 ± 9.00 |
History of hypertension (n, %) | 53 (91.4) |
Mean arterial pressure (mmHg) | 99.33 ± 13.25 |
Dyslipidemia n (%) | 41 (70.7) |
Smoking (n, %) | 35 (60.3) |
Family history (n, %) | 24 (41.4) |
Duration diabetes (years) | 10.47 ± 8.54 |
Diabetic polyneuropathy (n, %) | 13 (22.4) |
Diabetic retinopathy (n, %) | 8 (13.8) |
HbA1C (mmol/mol) | 52.55 ± 10.26 |
Fasting glucose (mg/dl) | 162.09 ± 53.55 |
Total cholesterol (mg/dl) | 191.64 ± 45.68 |
LDL-cholesterol (mg/dl) | 117.21 ± 36.45 |
HDL-cholesterol (mg/dl) | 43.78 ± 9.76 |
Triglycerides (mg/dl) | 179.57 ± 90.52 |
GFR (ml/min/1.73 m2) | 75.26 ± 23.27 |
NYHA classification (n, %) | |
   - I | 16 (27.6) |
   - II | 28 (48.3) |
   - III | 14 (24.1) |
   - IV | 0 (0) |
Medical therapy prior to coronary angiography n (%) | |
   - Metformin | 41 (70.7) |
   - Insulin | 21 (36.2) |
   - Sulfonylurea | 13 (22.4) |
   - Incretin-based therapy | 13 (22.4) |
   - Statin | 41 (70.7) |
   - ACE-inhibitor/ARB | 43 (74.1) |
   - ß-blocker | 45 (77.6) |
   - ASA | 54 (93.1) |